We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Pancreatic Cancer Cells Differ by Location and May Inform Targeted Treatments

Cancer cells.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.


Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, and the diagnosis has dramatically increased over the last decade. It is currently the seventh leading cause of cancer deaths in men and women globally and projected to be the third leading cause of cancer-related deaths world-wide by 2030. This increase is due to several factors such as an increase in obesity and diabetes.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Houston Methodist’s section chief of gastrointestinal medical oncology, Dr. Maen Abdelrahim, served as first and concept generating author for the article titled, “Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail,” published in NPJ Precision Oncology, an online journal in the Nature family of publications. The research team discovered that the anatomical location of the pancreatic tumor is a contributing factor for the outcomes of systematic therapy interventions.


Abdelrahim and his collaborators established a hypothesis that there is a difference in microenvironments of tumors in the pancreatic head versus the body and tail, particularly the immunotherapy receptors found on each section of the pancreas.


“By focusing on biology around the tumor and taking its location on the pancreas into account we can better evaluate our treatment options,” said Abdelrahim. “Rather than treating patients under the umbrella of pancreatic malignancy, a shift to a tumor location-based model can seriously alter how clinicians set up preliminary treatment plans.”


The team hopes this finding will help clinicians develop a more specific treatment plan and improve patient outcomes.

Reference: Abdelrahim M, Esmail A, Kasi A, et al. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. npj Precis Onc. 2024;8(1):85. doi: 10.1038/s41698-024-00571-4

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.